DIMERIX LIMITED — Capital/Financing Update 2012

Nov 11, 2012

==> picture [234 x 86] intentionally omitted <==

12 November 2012

Dear Shareholder

Non-Renounceable Rights Issue – Information for Shareholders

On 9 November 2012, Sun Biomedical Limited ( the Company ) announced to ASX that it was to undertake a non-renounceable Rights Issue of New Ordinary Shares to Eligible Shareholders.

Non-Renounceable Rights Issue

It is proposed that the Company issue approximately 165,570,004 New Ordinary Shares at a price of $0.007 per New Ordinary Share on the basis to acquire one New Ordinary Share for every one Share held at the Record Date of 19 November 2012. This Offer is fully underwritten by CPS Securities[1] ( the Underwriter ). The funds raised will be used as working capital and to identify and assess potential growth opportunities.

Applications

The Entitlement and Acceptance Form will be dispatched together with the Offer Document. Eligible Shareholders must complete the Entitlement and Acceptance Form in order to take up their Entitlements. Entitlement and Acceptance Forms must be properly completed and received by the Company’s Share Registry no later than 5.00pm (AEDT) on 7 December 2012 in order for Applicants to be issued New Ordinary Shares.

Quotation

New Ordinary Shares issued under the Offer Document will rank equally with the Company’s existing Shares. The Company has applied to ASX for quotation of the New Ordinary Shares on the Official List of the ASX. If approval is not granted by ASX within 3 months after the date of the Offer Document, the Company will not issue any New Ordinary Shares and will repay all Application monies without interest.

Enquiries

If you have any questions regarding this non-renounceable Rights Issue, please telephone the Company’s Share Registry, Computershare Investor Services Pty Limited, on 1 300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia).

The Directors recommend this non-renounceable Rights Issue to you.

Yours sincerely

==> picture [110 x 39] intentionally omitted <==

Terry Cuthbertson Chairman

1 Cunningham Peterson Sharbanee Securities Pty Ltd

Sun Biomedical Investor Communications Limited Computershare T: +61 1300 850 505 | ABN 18 001 285 230

==> picture [67 x 27] intentionally omitted <==

----- Start of picture text ----- ASX:SBNwww.sunbiomed.com----- End of picture text -----

Sun Biomedical Limited Non-Renounceable Rights Issue - Information sheet

The following information is provided to Shareholders in accordance with the ASX Listing Rules. Full details of the Offer are contained in the Offer Document which will be sent to Eligible Shareholders on or about 23 November 2012.

or about 23 November 2012.
Is securityholder approval required?	No.
Is theissuerenounceable or non-renounceable?	Non-Renounceable.
Ratio in which the+securities will be offered	1 New Ordinary Share for every 1 Share held at7.00pm AEDT time on the Record Date.
+Class of +securities issued or to be issued	Ordinary Shares.
Number of+securities issued or to be issued(if known) ormaximum number which maybe issued	165,570,004 Ordinary Shares.
Do the+securities rank equally in allrespects from thedate of allotment with an existingclass of securities	Yes.
+Record date to determine entitlements	7.00pm AEDT time on 19 November 2012.
Policy for deciding entitlements in relation to fractions	N/A
Names of countries in which the entity has+securityholders who will not be sent new issue documentsNote: Security holders must be told how their entitlementsare to be dealt with.Cross reference: rule 7.7.	British Virgin IslandsCanadaHong KongMauritiusNetherlandsSingaporeSouth AfricaSwitzerlandUkraineUnited Arab EmiratesUnited KingdomUnited States of America
Closing date for receipt of acceptances or renunciations	5.00pm AEDT time on 7 December 2012
Name of any underwriters	Cunningham Peterson Sharbanee Securities PtyLtd
Amount of any underwriting fee or commission	The Company is to pay the Underwriter amanagement fee of $50,000 (ex GST), acommission of 6.0% (ex GST) of the amountraised under the Rights Issue, and, subject to theListing Rules, intends to issue 17,857,143 optionsfor ordinary shares exercisable before 31December 2017 at $0.007.
Names of any brokers to the issue	Not applicable.
Fee or commission payable to the broker to the issue	Not applicable.
Amount of any handling fee payable to brokers who lodgeacceptances or renunciations on behalf of security holders	Not applicable.
Date entitlement and acceptance form and Offer Documentwill be sent to persons entitled	23 November 2012
If the entity has issued options, and the terms entitle optionholders to participate on exercise, the date on whichnotices will be sent to option holders	N/A
Despatch date	17 December 2012